{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["2022"],"submitter":["Wang R"],"pubmed_abstract":["<h4>Objective</h4>Zuojin pill (ZJP) is used as the classical prescription for a wide variety of digestive diseases. However, there is a lack of direct evidence for its use in the treatment of chronic nonatrophic gastritis (CNG). In particular, there is a lack of rigorous trials of randomized controlled designs. In this study, a randomized active-controlled clinical trial was performed to verify the efficacy and safety of ZJP in detail.<h4>Methods</h4>Patients with CNG were divided into the ZJP group and the Marzulene-S granule group. Patients were enrolled from September 2019 to February 2021 (ChiCTR2000040549). Endoscopy and histology scores were evaluated as the primary outcome measure. The <i>Helicobacter pylori</i> positive rate and the disappearance rate of symptoms were also measured"],"journal":["Evidence-based complementary and alternative medicine : eCAM"],"pagination":["2266023"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9010182"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and Safety of Zuojin Pill for the Treatment of Chronic Nonatrophic Gastritis: A Randomized Active-Controlled Clinical Trial."],"pmcid":["PMC9010182"],"pubmed_authors":["Rong W","Jing J","He T","Tian M","Wang R","Cui Y","Lu Z","Ma X","Wang Y","Wang Z","Yuan Z","Zhao Y"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and Safety of Zuojin Pill for the Treatment of Chronic Nonatrophic Gastritis: A Randomized Active-Controlled Clinical Trial.","description":"<h4>Objective</h4>Zuojin pill (ZJP) is used as the classical prescription for a wide variety of digestive diseases. However, there is a lack of direct evidence for its use in the treatment of chronic nonatrophic gastritis (CNG). In particular, there is a lack of rigorous trials of randomized controlled designs. In this study, a randomized active-controlled clinical trial was performed to verify the efficacy and safety of ZJP in detail.<h4>Methods</h4>Patients with CNG were divided into the ZJP group and the Marzulene-S granule group. Patients were enrolled from September 2019 to February 2021 (ChiCTR2000040549). Endoscopy and histology scores were evaluated as the primary outcome measure. The <i>Helicobacter pylori</i> positive rate and the disappearance rate of symptoms were also measured","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-25T22:58:00.185Z","creation":"2025-04-06T09:14:29.435Z"},"accession":"S-EPMC9010182","cross_references":{"pubmed":["35432566"],"doi":["10.1155/2022/2266023"]}}